Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Wrin

Showing results (91-100 of 106) with videos related to

Pageof 11
Sort By:
Medrxiv : the Preprint Server for Health Sciences|February 10, 2021
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individualsAlena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Nature|August 19, 2011
Broad neutralization coverage of HIV by multiple highly potent antibodiesLaura M Walker, Michael Huber, Katie J Doores, et al.
Immunity|November 23, 2017
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody LineageElise Landais, Ben Murrell, Bryan Briney, et al.
Plos Pathogens|January 15, 2016
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortElise Landais, Xiayu Huang, Colin Havenar-Daughton, et al.
Journal of Medical Virology|November 21, 2023
The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptomsAmanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Microbiology Spectrum|July 20, 2022
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic InfectionAmy J Schuh, Panayampalli S Satheshkumar, Stephanie Dietz, et al.
Journal of Virology|May 15, 2009
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmMelissa D Simek, Wasima Rida, Frances H Priddy, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19Michael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
Cell Reports|August 6, 2021
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptomsMichael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
JCI Insight|March 10, 2025
Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infectionsMiguel A Garcia-Knight, J Daniel Kelly, Scott Lu, et al.
Pageof 11

Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Medrxiv : the Preprint Server for Health Sciences|February 10, 2021
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individualsAlena J Markmann, Natasa Giallourou, D Ryan Bhowmik, et al.
Nature|August 19, 2011
Broad neutralization coverage of HIV by multiple highly potent antibodiesLaura M Walker, Michael Huber, Katie J Doores, et al.
Immunity|November 23, 2017
HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody LineageElise Landais, Ben Murrell, Bryan Briney, et al.
Plos Pathogens|January 15, 2016
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortElise Landais, Xiayu Huang, Colin Havenar-Daughton, et al.
Journal of Medical Virology|November 21, 2023
The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptomsAmanda M Buck, Amelia N Deitchman, Saki Takahashi, et al.
Microbiology Spectrum|July 20, 2022
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic InfectionAmy J Schuh, Panayampalli S Satheshkumar, Stephanie Dietz, et al.
Journal of Virology|May 15, 2009
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithmMelissa D Simek, Wasima Rida, Frances H Priddy, et al.
Medrxiv : the Preprint Server for Health Sciences|March 10, 2021
Long-Term SARS-CoV-2-Specific Immune and Inflammatory Responses Across a Clinically Diverse Cohort of Individuals Recovering from COVID-19Michael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
Cell Reports|August 6, 2021
Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptomsMichael J Peluso, Amelia N Deitchman, Leonel Torres, et al.
JCI Insight|March 10, 2025
Circulating neutralizing antibodies and SARS-CoV-2 variant replication following postvaccination infectionsMiguel A Garcia-Knight, J Daniel Kelly, Scott Lu, et al.
Pageof 11